Molecular Characterization of FLT3 Mutations in Acute Leukemia Patients

被引:10
|
作者
Ishfaq, Mariam [2 ]
Malik, Arif [2 ]
Faiz, Mariam [4 ]
Sheikh, Ishfaq Ahmad [7 ]
Asif, Muhammad [3 ]
Khan, Muhammad Nasrullah [5 ]
Qureshi, Muhammad Saeed [5 ]
Zahid, Sara [2 ]
Manan, Abdul [2 ]
Arooj, Mahwish [2 ]
Qazi, Mahmood Husain [6 ]
Chaudhary, Adeel [1 ]
Alqahtani, Mohammed Hussain [1 ]
Rasool, Mahmood [1 ]
机构
[1] King Abdulaziz Univ, CEGMR, Jeddah 21413, Saudi Arabia
[2] Univ Lahore, Inst Mol Biol & Biotechnol, Lahore, Pakistan
[3] BUITEMS, Dept Biotechnol & Informat, Quetta, Pakistan
[4] Univ Lahore, Dept Pathol, Mol Genet Lab, INMOL Hosp, Lahore, Pakistan
[5] Univ Lahore, Allama Iqbal Med Coll, Lahore, Pakistan
[6] Univ Lahore, Ctr Res Mol Med, Lahore, Pakistan
[7] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah 21413, Saudi Arabia
关键词
Acute leukemia; FLT3/ITD; FAB subtypes; INTERNAL TANDEM DUPLICATION; ACUTE MYELOID-LEUKEMIA; MYELOGENOUS LEUKEMIA; GENE; ASSOCIATION; ACTIVATION; IMPACT;
D O I
10.7314/APJCP.2012.13.9.4581
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fms-like tyrosine kinase 3 (FLT3) performs a vital role in the pathogenesis of hematopoietic malignancies. Therefore in recent times, the focus of several studies was on use of FLT3 as a prognostic marker. The present study investigated the molecular characterization and incidence of FLT3 mutations in acute leukemia patients in Pakistan. A total of 55 patients were studied, of which 25 were suffering from acute lymphoblastic leukemia (ALL) and 30 were suffering from acute myeloid leukemia (AML). The polymerase chain reaction demonstrated FLT3/ITD mutations in 1 (4%) of 25 ALL patients, a male with the L2 subtype. In AML cases the rate was 4 (13.3%) of 30, three males and one female. The AML-M4 subtype was found in three and the AML M2 subtype in the other. In the AML cases, a statistically significant (p=0.009) relationship was found between WBC (109/L) and FLT3/ITD positivity. However, no significant relationship was found with other clinical parameters (p>0.05). In acute myeloid leukemia (AML) FLT3/ITD+ mutation was more prevalent in elderly patients 31-40 age groups, 21-30 and 51-60 age groups respectively. In acute lymphoblastic leukemia (ALL) statistically no significant relationship was found between clinical features and FLT3/ITD positivity (p>0.05). However, in acute lymphoblastic leukemia (ALL) FLT3/ITD+ mutation was more commonly found in age groups of 21-30.
引用
收藏
页码:4581 / 4585
页数:5
相关论文
共 50 条
  • [41] Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model
    Chan, Perry M.
    PROTEIN & CELL, 2011, 2 (02) : 108 - 115
  • [42] FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis
    Fei, Xinhong
    Zhang, Shuqin
    Gu, Jiangying
    Wang, Jingbo
    CANCER MEDICINE, 2023, 12 (06): : 6877 - 6888
  • [43] Disease diversity and FLT3 mutations
    Smith, Catherine Choy
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (52) : 20860 - 20861
  • [44] Deciphering the molecular mechanism of FLT3 resistance mutations
    Georgoulia, Panagiota S.
    Bjelic, Sinisa
    Friedman, Ran
    FEBS JOURNAL, 2020, 287 (15) : 3200 - 3220
  • [45] Importance of PTM of FLT3 in acute myeloid leukemia
    Liu, Jianwei
    Gu, Jianguo
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2024, 56 (08) : 1199 - 1207
  • [46] Bench to Bedside Targeting of FLT3 in Acute Leukemia
    Pratz, Keith W.
    Levis, Mark J.
    CURRENT DRUG TARGETS, 2010, 11 (07) : 781 - 789
  • [47] A review of FLT3 inhibitors in acute myeloid leukemia
    Zhao, Jennifer C.
    Agarwal, Sonal
    Ahmad, Hiba
    Amin, Kejal
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    BLOOD REVIEWS, 2022, 52
  • [48] FLT3 Inhibitors in the Management of Acute Myeloid Leukemia
    Zappone, E.
    Defina, M.
    Aprile, L.
    Bartalucci, G.
    Gozzetti, A.
    Bocchia, M.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (08) : 1028 - 1032
  • [49] The Development of FLT3 Inhibitors in Acute Myeloid Leukemia
    Garcia, Jacqueline S.
    Stone, Richard M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) : 663 - +
  • [50] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Mori, Masamichi
    Kaneko, Naoki
    Ueno, Yoko
    Yamada, Masaki
    Tanaka, Ruriko
    Saito, Rika
    Shimada, Itsuro
    Mori, Kenichi
    Kuromitsu, Sadao
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565